Go Pro

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$43.34 -0.57 (-1.30%)
As of 09:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Boston Scientific Stock (NYSE:BSX)

Advanced

Key Stats

Today's Range
$43.65
$43.65
50-Day Range
$42.71
$52.02
52-Week Range
$42.20
$105.65
Volume
162,728 shs
Average Volume
18.54 million shs
Market Capitalization
$62.81 billion
P/E Ratio
17.60
Dividend Yield
N/A
Price Target
$71.04
Consensus Rating
Moderate Buy

Company Overview

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world. The company is headquartered in Marlborough, Massachusetts, and operates through a global network of research, manufacturing, sales and distribution facilities.

AI Generated. May Contain Errors.

Boston Scientific Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 97% of companies evaluated by MarketBeat, and ranked 8th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 24 buy ratings, 5 hold ratings, and 2 sell ratings.

  • Upside Potential

    Boston Scientific has a consensus price target of $71.46, representing about 62.5% upside from its current price of $43.97.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 3.95% in the coming year, from $3.29 to $3.42 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 17.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 17.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.86.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    3.34% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.29, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 74.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • News Sentiment

    Boston Scientific has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Boston Scientific this week, compared to 10 articles on an average week.
  • Search Interest

    Only 79 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.
  • MarketBeat Follows

    26 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.
  • Cluster Insider Buying

    3 insiders have purchased shares of Boston Scientific in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $9,385,210.00 in company stock, which represents 0.0147% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,385,210.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.34% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Stock News Headlines

Has BSX Stock Finally Hit Bottom?
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
Why Pay More For Stryker When BSX Stock Is On Sale?
Promising Medical Stocks To Research - September 10th
Boston Scientific: $43 Finally Prices In A Bad 2026
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $95.29 at the beginning of the year. Since then, BSX shares have decreased by 53.9% and is now trading at $43.9680.

Boston Scientific Corporation (NYSE:BSX) announced its earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business's quarterly revenue was up 7.5% compared to the same quarter last year.
Read the conference call transcript
.

Boston Scientific's Board of Directors initiated a share repurchase program on Monday, May 18th 2026, which permits the company to buy back $5,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its shares are undervalued.

Boston Scientific subsidiaries include these companies: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Boston Scientific's top institutional investors include BlackRock Inc. (8.95%), Primecap Management Co. CA (3.49%), Jupiter Topco LLC (1.30%) and Wellington Management Group LLP (1.06%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Eric Francis Yves Thepaut, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jeffrey B Mirviss, Ellen M Zane, Arthur C Butcher, John Bradley Sorenson, David C Habiger, Yoshiaki Fujimori, Cheryl Pegus and Charles J Dockendorff.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
7/29/2026
Today
9/17/2026
Next Earnings (Estimated)
10/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:BSX
CIK
885725
Employees
59,000
Year Founded
1979

Price Target and Rating

High Price Target
$118.00
Low Price Target
$50.00
Potential Upside/Downside
+62.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
31 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.47
Trailing P/E Ratio
17.80
Forward P/E Ratio
13.36
P/E Growth
1.02
Net Income
$2.90 billion
Net Margins
17.50%
Pretax Margin
18.39%
Return on Equity
19.28%
Return on Assets
10.89%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
1.24
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$20.07 billion
Price / Sales
3.17
Cash Flow
$4.04 per share
Price / Cash Flow
10.87
Book Value
$16.49 per share
Price / Book
2.67

Miscellaneous

Outstanding Shares
1,449,230,000
Free Float
1,444,303,000
Market Cap
$63.72 billion
Optionable
Optionable
Beta
0.57

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NYSE:BSX) was last updated on 9/17/2026 by MarketBeat.com Staff.
From Our Partners